Abstract: Piperazine derivatives of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in therapy as 5-HT1B antagonists. W,Y,Ra-Re are so defined in the application.

Abstract: The invention relates to compounds of formula (I) having Vanilloid Receptor (VR1) antagonist activity, processes for their preparation, to compositions containing them and to their use in the treatment of various disorders.

Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof are disclosed: 1

Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof are disclosed: in which Ra is a group of formula (i) wherein P1 is phenyl, naphthyl or heteroaryl; R1 is halogen, C1-6alkyl, C3-6cycloalkyl, COC1-6alkyl, C1-6alkoxy, hydroxy, hydroxyC1-6alkyl, nitro, haloC1-6alkyl, cyano, SR6, SOR6, SO2R6, SO2NR6R7, CO2R6, CONR6R7, OCONR6COR7, NR6r7, NR6COR7, NR6CO2R7, NR6SO2R7, NR6CONR7R8, CH2NR6COR7, CH2NR6CO2R7, CH2NR6SO2R7, CR6═NOR7 where R6, R7 and R8 are independently hydrogen or C1-6alkyl, a is 1, 1, 2, or 3; or Ra is a group of formula (ii) where P2 is phenyl, naphthyl, heteroaryl or a 5 to 7 membered heterocyclic ring; P3 is phenyl, naphthyl or heteroaryl; R2 is a defined above for R1 in formula (I) or R2 is heteroaryl optionally substituted By C1alkyl, halogen or COC1-6alkyl or is a 5-7 membered heterocyclic ring optionally substituted by oxo; R3 is halogen, C1-6alkyl, C3-6cycloalkyl, C1-6alkyl, COC1-6alkyl, hydroxy, intro, haloC1-6alkyl, cyano, CO2R6, CONR6R7, NR6R7 where R6 and R7 are as d

Abstract: Novel carboxamide derivatives having CNS activity, processes for their preparation and their use as medicaments.

Abstract: Piperazine derivatives of formula(1), processes for their preparation, pharmaceutical compositions containing them in the treatment of CNS and other disorders and in their use in therapy as 5-HT1B antagonists are disclosed herein.

Abstract: The invention relates to novel compounds having Vanilloid Receptor (VR1) antagonist activity, processes for their preparation, to compositions containing them and to their use in the treatment of various disorders.

Abstract: The invention relates to heterocyclic compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders such as anxiety.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof: 1

Abstract: Novel sulphonamide derivatives having CNS activity, processes for their preparation and their use as medicaments are disclosed.

Abstract: The invention relates to heterocyclic compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders such as anxiety.

Abstract: Novel sulphonamide derivatives having CNS activity, processes for their preparation and their use as medicaments.

Abstract: Novel sulphonamide derivatives having CNS activity, processes for their preparation and their use as medicaments are disclosed.

Abstract: The invention relates to compounds which are ligands for 5HT1, of formula (I) Wherein L, Q, Ra, Rb and Ry are as defined in the specification, processes for their preparation and their pharmaceutical composition as well as their use in the treatment of anxiety and depression.

Abstract: Novel carboxamide derivatives having CNS activity, processes for their preparation and their use as medicaments

Abstract: A compound of formula (I) or a salt thereof: wherein: P1 is pyridiyl; P2 is phenyl; A is a bond or a chain of 1 to 5 atoms optionally substituted by C1-6 alkyl; R1 and R2 groups are each independently hydrogen, C1-6alkyl optionally substituted by NR12R13, C2-6alkenyl, C2-6alkynyl, cyano, halogen, CF3, NR12R13, CHO, OCF3, COR14, CH2OR14 or OR14 where R12, R13 and R14 are independently hydrogen or C1-6alkyl; n and m are independently 0, 1 or 2; R3 is hydrogen or C1-6 alkyl; R4 is a group of formula (i): in which: R6 and R7 are independently hydrogen, C1-6 alkyl optionally substituted by one or more fluorine atoms, C1-6alkylthio, C1-6alkoxy or halogen.

Abstract: Novel bicyclic aryl/bicyclic heterocyclic ring containing compounds having a combined 5HT.sub.1A, 5HT.sub.1B and 5HT.sub.1D receptor antagonistic activity are provided.

Abstract: Compounds of formula(I) where B is oxygen or sulphur, D is nitrogen, R.sup.6 and R.sup.7 forms a ring, m is 2, R is a substituted latam ring of formula (i) ##STR1## where p is 1, P is a substituted or unsubstituted bicyclic ring containing one or two heteroatoms or P is an unsbustituted or substituted 5- to 7-memebered saturated ring containing one or two heteroatoms; X, Y, Z, E, G, R.sup.3, R.sup.4, R.sup.5, R.sup.8, R.sup.9, and R.sup.10 are as defined in the specification.

Abstract: Compounds of formula (I) in which B is oxygen, CR.sup.17 R.sup.18 or NR.sup.19 where R.sup.17, R.sup.18 and R.sup.19 are independently hydrogen or C.sub.1-6 alkyl or B is a group S(O).sub.b where b is 1, 2, or 3; and R.sup.6 is a group --(CH.sub.2).sub.p --R.sup.15 where R.sup.15 is OR.sup.16 or SR.sup.16 is hydrogen or C.sub.1-6 alkyl or R.sup.15 is NR.sup.10 R.sup.11 where R.sup.10 and R.sup.11 are as defined for R.sup.1 ; have been found to exhibit 5TH.sub.1B antagonist activity.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## and their use as pharmaceuticals in the treatment of gastrointestinal disorders, cardiovascular disorders and CNS disorders.